ArticleJournal of neuro-oncology2000
Matrix metalloproteinase 2 (MMP-2) immunoreactive protein is associated with poor grade and survival in brain neoplasms.
Article in Journal of neuro-oncology, 2000. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 79 citations in OpenAlex.
- Phase II trial of temozolomide plus marimastat for recurrent anaplastic gliomas: a relationship among efficacy, joint toxicity and anticonvulsant status.Journal of neuro-oncology · 2006Trial
- The genetic association between celiac disease and risk of functional dyspepsia: A Mendelian randomization study.Medicine · 2026Article
- Circulating PDIA4, MMP-2, MMP-9, and Claudin-2 in Vitamin D-Deficient Patients with Brain Tumors: An Exploratory Clinical Pilot Study.Journal of clinical medicine · 2026Article
- Article
- Identification of antimicrobial peptides from the Ambystoma mexicanum displaying antibacterial and antitumor activity.PloS one · 2025Article
- Natural Products as Regulators against Matrix Metalloproteinases for the Treatment of Cancer.Biomedicines · 2024Review
- Membranous type matrix metalloproteinase 16 induces human prostate cancer metastasis.Oncology letters · 2017Article
- Article
- Integrating the glioblastoma microenvironment into engineered experimental models.Future science OA · 2017Review
- Article
- Expression and prognostic impact of matrix metalloproteinase-2 (MMP-2) in astrocytomas.PloS one · 2017Article
- [Tumor Cells and Micro-environment in Brain Metastases].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2016Review
- Matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs) in the tumors of central nervous system (CNS).Journal of neural transmission (Vienna, Austria : 1996) · 2014Review
- Association of matrix metalloproteinase 2 plasma level with response and survival in patients treated with bevacizumab for recurrent high-grade glioma.Neuro-oncology · 2014Article
- Inhibition of MMP14 potentiates the therapeutic effect of temozolomide and radiation in gliomas.Cancer medicine · 2013Article
- Proteins involved in regulating bone invasion in skull base meningiomas.Acta neurochirurgica · 2013Article
- Innovative therapeutic strategies in the treatment of brain metastases.International journal of molecular sciences · 2013Article
- Regulation of cell proliferation and migration in glioblastoma: new therapeutic approach.Frontiers in oncology · 2013Article
- FRK controls migration and invasion of human glioma cells by regulating JNK/c-Jun signaling.Journal of neuro-oncology · 2012Article
- The molecular biology of brain metastasis.Journal of oncology · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
unlabelledMatrix metalloproteinases play an important role in the invasion of tumor cells and the progression of cancer. The 72 kDa type IV collagenase, a matrix metalloproteinase 2 (MMP-2) has been shown to contribute to the invasion and metastasis in diverse malignant neoplasms. OBJECT: To elaborate the potential role of MMP-2 in brain tumor invasion we studied the expression and localization of this enzyme protein in 101 brain tumors representing different types of brain neoplasms. For the first time, we also correlated the expression of MMP-2 protein to patient survival.
methodsUsing immunohistochemistry and a monoclonal antibody specific for MMP-2 we found that MMP-2 protein was primarily localized in tumor cells and vasculature cells as well as inflammatory cells. The expression of MMP-2 was absent or negligible in benign tumors (pilocytic astrocytoma and meningioma). Thirty-three percent (6/18) of astrocytomas, 38% (3/8) of anaplastic astrocytomas, 14% (1/7) of anaplastic oligodendrogliomas, 54% (19/35) of glioblastomas and 100% (6/6) of metastatic brain tumors were positive for MMP-2. A correlation between MMP-2 expression and survival was found in malignant brain tumors. The mean survival of patients with an MMP-2 negative tumor was 36 months, when it was only 7-14 months in patients with an MMP-2 positive tumor.
conclusionsOur data suggest that MMP-2 is associated with histological malignancy and poor survival in brain tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.